Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Multicenter, Open-Label Study to Assess the Pharmacokinetics, Safety, and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-Course Juvenile Idiopathic Arthritis

    Summary
    EudraCT number
    2009-018027-33
    Trial protocol
    Outside EU/EEA  
    Global end of trial date
    08 Apr 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    12 Oct 2024
    First version publication date
    12 Oct 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    RA0043
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01550003
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    UCB Biopharma SRL
    Sponsor organisation address
    Allée de la Recherche 60, Brussels, Belgium, 1070
    Public contact
    Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ucb.com
    Scientific contact
    Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ucb.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    31 May 2024
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    08 Apr 2024
    Global end of trial reached?
    Yes
    Global end of trial date
    08 Apr 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    Evaluate the Pharmacokinetic (PK) and safety including the immunogenicity of certolizumab pegol (CZP) administered subcutaneously (sc) in children and adolescents with moderate to severe polyarticular-course juvenile idiopathic arthritis (JIA)
    Protection of trial subjects
    During the conduct of the study all participants were closely monitored.
    Background therapy
    Background therapy as permitted in the protocol.
    Evidence for comparator
    Not applicable
    Actual start date of recruitment
    08 Mar 2012
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Argentina: 2
    Country: Number of subjects enrolled
    Brazil: 5
    Country: Number of subjects enrolled
    Canada: 15
    Country: Number of subjects enrolled
    Chile: 1
    Country: Number of subjects enrolled
    Mexico: 38
    Country: Number of subjects enrolled
    Russian Federation: 64
    Country: Number of subjects enrolled
    United States: 68
    Worldwide total number of subjects
    193
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    86
    Adolescents (12-17 years)
    107
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study started to enroll participants in March 2012 and concluded in April 2024.

    Pre-assignment
    Screening details
    Participant Flow refers to the Safety Set.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Any CZP Dose - Weight group: 10 - < 20 kg
    Arm description
    Participants received Certolizumab Pegol (CZP) subcutaneously (sc) as a fixed dose based on their body weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.
    Arm type
    Experimental

    Investigational medicinal product name
    Certolizumab Pegol
    Investigational medicinal product code
    CDP870
    Other name
    CZP, Cimzia®
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received CZP at pre-defined timepoints.

    Arm title
    Any CZP Dose - Weight group: 20 - <40 kg
    Arm description
    Participants received CZP sc as a fixed dose based on their body weight Q2W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.
    Arm type
    Experimental

    Investigational medicinal product name
    Certolizumab Pegol
    Investigational medicinal product code
    CDP870
    Other name
    CZP, Cimzia®
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received CZP at pre-defined timepoints.

    Arm title
    Any CZP Dose - Weight group: >= 40 kg
    Arm description
    Participants received CZP sc as a fixed dose based on their body weight Q2W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.
    Arm type
    Experimental

    Investigational medicinal product name
    Certolizumab Pegol
    Investigational medicinal product code
    CDP870
    Other name
    CZP, Cimzia®
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received CZP at pre-defined timepoints.

    Number of subjects in period 1
    Any CZP Dose - Weight group: 10 - < 20 kg Any CZP Dose - Weight group: 20 - <40 kg Any CZP Dose - Weight group: >= 40 kg
    Started
    18
    63
    112
    Original CZP Dose
    7
    34
    64
    Reduced CZP Dose
    11
    29
    48
    Completed
    0
    0
    0
    Not completed
    18
    63
    112
         Patient reached adulthood
    -
    1
    -
         By medical decision and approved by the sponsor
    -
    -
    1
         Subject is in college/unable to come to visits
    -
    -
    1
         Missing
    1
    -
    2
         Site closure
    -
    2
    -
         Sponsor's decision
    1
    5
    4
         Study closed
    -
    1
    -
         Adverse event, non-fatal
    -
    9
    15
         Switching to adult rheumatologist
    -
    -
    1
         Non-compliance
    -
    -
    1
         Protocol Noncompliance
    1
    -
    -
         Protocol deviation
    -
    3
    2
         Study closure
    -
    1
    1
         Transitioned to adult rheumatology
    -
    -
    1
         Discontinuation
    -
    1
    -
         Treatment or 12 week follow up visit completed
    -
    -
    1
         Patient not compliance
    -
    -
    1
         Per Sponsor request
    1
    -
    1
         Subject mother passed away
    -
    1
    -
         Subject moved to rheumatology and out of study
    -
    1
    1
         Early discontinuation at request of sponsor
    -
    2
    4
         Sponsor's order
    -
    3
    3
         Subject was able to obtain commercial cimzia
    -
    -
    1
         Pregnancy
    -
    1
    -
         Lost to follow-up
    1
    4
    8
         Consent withdrawn
    2
    11
    23
         Study closure as announced by sponsor
    7
    6
    24
         Patient transition to adult care
    -
    -
    1
         Lack of efficacy
    4
    11
    15

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Any CZP Dose - Weight group: 10 - < 20 kg
    Reporting group description
    Participants received Certolizumab Pegol (CZP) subcutaneously (sc) as a fixed dose based on their body weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.

    Reporting group title
    Any CZP Dose - Weight group: 20 - <40 kg
    Reporting group description
    Participants received CZP sc as a fixed dose based on their body weight Q2W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.

    Reporting group title
    Any CZP Dose - Weight group: >= 40 kg
    Reporting group description
    Participants received CZP sc as a fixed dose based on their body weight Q2W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.

    Reporting group values
    Any CZP Dose - Weight group: 10 - < 20 kg Any CZP Dose - Weight group: 20 - <40 kg Any CZP Dose - Weight group: >= 40 kg Total
    Number of subjects
    18 63 112 193
    Age Categorical
    Units: participants
        24 months - <12 years
    18 55 13 86
        12 - <18 years
    0 8 99 107
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    5.4 ( 1.3 ) 9.1 ( 2.0 ) 14.5 ( 2.2 ) -
    Sex: Female, Male
    Units: participants
        Female
    11 43 76 130
        Male
    7 20 36 63

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Any CZP Dose - Weight group: 10 - < 20 kg
    Reporting group description
    Participants received Certolizumab Pegol (CZP) subcutaneously (sc) as a fixed dose based on their body weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.

    Reporting group title
    Any CZP Dose - Weight group: 20 - <40 kg
    Reporting group description
    Participants received CZP sc as a fixed dose based on their body weight Q2W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.

    Reporting group title
    Any CZP Dose - Weight group: >= 40 kg
    Reporting group description
    Participants received CZP sc as a fixed dose based on their body weight Q2W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.

    Subject analysis set title
    Reduced CZP Dose -Weight group: 10 - <20 kg
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Participants received CZP 50 milligrams (mg) sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 50 mg sc Q4W (maintenance dose) from Week 8 onwards.

    Subject analysis set title
    Reduced CZP Dose - Weight group: 20 - <40 kg
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Participants received CZP 100 mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 50 mg sc Q2W (maintenance dose) from Week 6 onwards.

    Subject analysis set title
    Reduced CZP Dose - Weight group: >=40 kg
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Participants received CZP 200 mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 100 mg sc Q2W (maintenance dose) from Week 6 onwards.

    Subject analysis set title
    Original CZP dose - Weight group: 10 - <20 kg
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Participants received CZP 100 mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 50 mg sc Q2W (maintenance dose) from Week 6 onwards.

    Subject analysis set title
    Original CZP Dose - Weight group: 20 - <40 kg
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Participants received CZP 200 mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 100 mg sc Q2W (maintenance dose) from Week 6 onwards.

    Subject analysis set title
    Original CZP Dose - Weight group: >=40 kg
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Participants received CZP 400 mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200 mg sc Q2W (maintenance dose) from Week 6 onwards.

    Subject analysis set title
    Reduced CZP Dose
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Participants received reduced CZP sc as a fixed dose based on their body weight Q2W or Q4W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.

    Subject analysis set title
    Original CZP dose
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Participants received original CZP sc as a fixed dose based on their body weight Q2W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.

    Primary: Certolizumab Pegol (CZP) Plasma Concentration level at Week 16

    Close Top of page
    End point title
    Certolizumab Pegol (CZP) Plasma Concentration level at Week 16 [1]
    End point description
    Certolizumab Pegol (CZP) plasma concentration level was measured in micrograms per mililiter (ug/ml). The Pharmacokinetic Per-Protocol (PK-PP) Set was a subset of the SS consisting of those study participants who took at least 1 dose of study medication, provided measurable plasma CZP concentration samples (with recorded sampling date/time or for which date/time can be reasonably assumed). Here, " Number of Participants Analyzed" signifies participants evaluable for this outcome measure.
    End point type
    Primary
    End point timeframe
    Week 16
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized as descriptive statistics only.
    End point values
    Reduced CZP Dose -Weight group: 10 - <20 kg Reduced CZP Dose - Weight group: 20 - <40 kg Reduced CZP Dose - Weight group: >=40 kg Original CZP dose - Weight group: 10 - <20 kg Original CZP Dose - Weight group: 20 - <40 kg Original CZP Dose - Weight group: >=40 kg
    Number of subjects analysed
    10
    24
    36
    5
    29
    49
    Units: ug/ml
        geometric mean (confidence interval 95%)
    1.6166 (0.4720 to 5.5368)
    9.2277 (5.1453 to 16.5491)
    13.8928 (11.0030 to 17.5416)
    22.9060 (13.3380 to 39.3374)
    25.7752 (16.9024 to 39.3058)
    33.5680 (25.7883 to 43.6945)
    No statistical analyses for this end point

    Primary: Certolizumab Pegol (CZP) Plasma Concentration level at Week 48

    Close Top of page
    End point title
    Certolizumab Pegol (CZP) Plasma Concentration level at Week 48 [2]
    End point description
    Certolizumab Pegol (CZP) plasma concentration level was measured in ug/mL. The Pharmacokinetic Per-Protocol (PK-PP) Set was a subset of the SS consisting of those study participants who took at least 1 dose of study medication, provided measurable plasma CZP concentration samples (with recorded sampling date/time or for which date/time can be reasonably assumed). Here, "Number of Participants Analyzed" signifies participants evaluable for this outcome measure. Here, 99999 signifies that as pre-specified in the SAP, Geometric Mean and 95% confidence interval were not calculated if the number of values below lower limit of quantification (LLOQ) was greater than (>)1/3. If n less than (<) 3, only the minimum and maximum were reported, other statistics were not calculated.
    End point type
    Primary
    End point timeframe
    Week 48
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized as descriptive statistics only.
    End point values
    Reduced CZP Dose -Weight group: 10 - <20 kg Reduced CZP Dose - Weight group: 20 - <40 kg Reduced CZP Dose - Weight group: >=40 kg Original CZP dose - Weight group: 10 - <20 kg Original CZP Dose - Weight group: 20 - <40 kg Original CZP Dose - Weight group: >=40 kg
    Number of subjects analysed
    9
    24
    31
    2
    12
    25
    Units: ug/ml
        geometric mean (confidence interval 95%)
    4.7404 (1.7596 to 12.7710)
    8.4459 (5.0002 to 14.2661)
    12.2987 (8.6950 to 17.3962)
    99999 (99999 to 99999)
    20.7048 (11.1744 to 38.3636)
    25.5940 (14.6913 to 44.5878)
    No statistical analyses for this end point

    Primary: Number of participants with Anti-Certolizumab Pegol (anti-CZP) Antibody level at Week 16

    Close Top of page
    End point title
    Number of participants with Anti-Certolizumab Pegol (anti-CZP) Antibody level at Week 16 [3]
    End point description
    Number of participants with anti-CZP antibodies were reported. Safety Set (SS) consisted of all study participants in the Enrolled Set (ES) who have received at least 1 dose of study medication. Here, "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.
    End point type
    Primary
    End point timeframe
    Week 16
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized as descriptive statistics only.
    End point values
    Reduced CZP Dose Original CZP dose
    Number of subjects analysed
    84
    97
    Units: participants
    69
    77
    No statistical analyses for this end point

    Primary: Number of participants with Anti-Certolizumab Pegol (anti-CZP) Antibody level at Week 48

    Close Top of page
    End point title
    Number of participants with Anti-Certolizumab Pegol (anti-CZP) Antibody level at Week 48 [4]
    End point description
    Number of participants with anti-CZP antibodies were reported. Safety Set (SS) consisted of all study participants in the Enrolled Set (ES) who have received at least 1 dose of study medication. Here, "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.
    End point type
    Primary
    End point timeframe
    Week 48
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized as descriptive statistics only.
    End point values
    Reduced CZP Dose Original CZP dose
    Number of subjects analysed
    72
    60
    Units: participants
    58
    47
    No statistical analyses for this end point

    Primary: Number of participants with serious treatment-emergent adverse events (TEAEs) during the study

    Close Top of page
    End point title
    Number of participants with serious treatment-emergent adverse events (TEAEs) during the study [5]
    End point description
    A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: results in deaths, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect and other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. TEAEs are defined as AEs starting on or after first administration of CZP and up to 70 days after last dose of study medication. Safety Set (SS) consisted of all study participants in the Enrolled Set (ES) who have received at least 1 dose of study medication.
    End point type
    Primary
    End point timeframe
    From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)
    Notes
    [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized as descriptive statistics only.
    End point values
    Any CZP Dose - Weight group: 10 - < 20 kg Any CZP Dose - Weight group: 20 - <40 kg Any CZP Dose - Weight group: >= 40 kg
    Number of subjects analysed
    18
    63
    112
    Units: participants
    5
    20
    21
    No statistical analyses for this end point

    Primary: Number of participants with treatment-emergent adverse events (TEAEs) leading to permanent withdrawal of the Investigational Medicinal Product (IMP) during the study

    Close Top of page
    End point title
    Number of participants with treatment-emergent adverse events (TEAEs) leading to permanent withdrawal of the Investigational Medicinal Product (IMP) during the study [6]
    End point description
    An AE is any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an IMP, whether or not related to the IMP. TEAEs are defined as AEs starting on or after first administration of CZP and up to 70 days after last dose of study medication. TEAEs leading to permanent withdrawal of the IMP during the study were reported in this outcome measure. Safety Set (SS) consisted of all study participants in Enrolled Set (ES) who have received at least 1 dose of study medication.
    End point type
    Primary
    End point timeframe
    From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)
    Notes
    [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized as descriptive statistics only.
    End point values
    Any CZP Dose - Weight group: 10 - < 20 kg Any CZP Dose - Weight group: 20 - <40 kg Any CZP Dose - Weight group: >= 40 kg
    Number of subjects analysed
    18
    63
    112
    Units: participants
    0
    9
    16
    No statistical analyses for this end point

    Secondary: Percentage of Participants meeting American College of Rheumatology Pediatric 30 % (PedACR30) Response Criteria at Week 16

    Close Top of page
    End point title
    Percentage of Participants meeting American College of Rheumatology Pediatric 30 % (PedACR30) Response Criteria at Week 16
    End point description
    PedACR30-at least 30% improvement from baseline in 3 of any 6 core set measures, with no more than 1 of remaining variables worsening by >30%: • Number of joints with active arthritis • Number of joints with limitation of range of motion • Physician’s Global Assessment of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor) • CHAQ (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability]) • Parent’s Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor) • C-reactive protein(CRP) FAS: all study participants in SS who have no more than one of 6 core components missing at baseline (count of joints with active arthritis, count of joints with limitation of range of motion, Physician’s Global Assessment of Disease Activity score, CHAQ score, Parent’s Global Assessment of Overall Well-Being score and CRP result) for calculating PedACR30/50/70/90.
    End point type
    Secondary
    End point timeframe
    Week 16
    End point values
    Any CZP Dose - Weight group: 10 - < 20 kg Any CZP Dose - Weight group: 20 - <40 kg Any CZP Dose - Weight group: >= 40 kg
    Number of subjects analysed
    18
    63
    112
    Units: percentage of participants
        number (confidence interval 95%)
    83.3 (58.6 to 96.4)
    77.8 (65.5 to 87.3)
    79.5 (70.8 to 86.5)
    No statistical analyses for this end point

    Secondary: Percentage of Participants meeting American College of Rheumatology Pediatric 70 % (PedACR70) Response Criteria at Week 16

    Close Top of page
    End point title
    Percentage of Participants meeting American College of Rheumatology Pediatric 70 % (PedACR70) Response Criteria at Week 16
    End point description
    PedACR70- at least 70% improvement from baseline in 3 of any 6 following core set measures, with no more than 1 of remaining variables worsening by >30%: • Number of joints with active arthritis • Number of joints with limitation of range of motion • Physician’s Global Assessment of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor) • CHAQ (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability]) • Parent’s Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor) • CRP FAS consisted of all study participants in SS who have no more than one of 6 core components missing at baseline (count of joints with active arthritis, count of joints with limitation of range of motion, Physician’s Global Assessment of Disease Activity score, CHAQ score, Parent’s Global Assessment of Overall Well-Being score and CRP result) for calculating PedACR30/50/70/90.
    End point type
    Secondary
    End point timeframe
    Week 16
    End point values
    Any CZP Dose - Weight group: 10 - < 20 kg Any CZP Dose - Weight group: 20 - <40 kg Any CZP Dose - Weight group: >= 40 kg
    Number of subjects analysed
    18
    63
    112
    Units: percentage of participants
        number (confidence interval 95%)
    44.4 (21.5 to 69.2)
    57.1 (44.0 to 69.5)
    54.5 (44.8 to 63.9)
    No statistical analyses for this end point

    Secondary: Percentage of Participants meeting American College of Rheumatology Pediatric 50 % (PedACR50) Response Criteria at Week 16

    Close Top of page
    End point title
    Percentage of Participants meeting American College of Rheumatology Pediatric 50 % (PedACR50) Response Criteria at Week 16
    End point description
    PedACR50- at least 50% improvement from baseline in 3 of any 6 core set measures, with no more than 1 of remaining variables worsening by >30%: • Number of joints with active arthritis • Number of joints with limitation of range of motion • Physician’s Global Assessment (PGA) of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor) • Childhood Health Assessment Questionnaire (CHAQ) (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability]) • Parent’s Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor) • CRP FAS:all study participants in SS who have no more than one of 6 core components missing at baseline (count of joints with active arthritis, count of joints with limitation of range of motion, PGA of Disease Activity score, CHAQ score, Parent’s Global Assessment of Overall Well-Being score and CRP result) for calculating PedACR30/50/70/90.
    End point type
    Secondary
    End point timeframe
    Week 16
    End point values
    Any CZP Dose - Weight group: 10 - < 20 kg Any CZP Dose - Weight group: 20 - <40 kg Any CZP Dose - Weight group: >= 40 kg
    Number of subjects analysed
    18
    63
    112
    Units: percentage of participants
        number (confidence interval 95%)
    66.7 (41.0 to 86.7)
    71.4 (58.7 to 82.1)
    74.1 (65.0 to 81.9)
    No statistical analyses for this end point

    Secondary: Percentage of Participants meeting American College of Rheumatology Pediatric 90 % (PedACR90) Response Criteria at Week 16

    Close Top of page
    End point title
    Percentage of Participants meeting American College of Rheumatology Pediatric 90 % (PedACR90) Response Criteria at Week 16
    End point description
    PedACR90- at least 90% improvement from baseline in 3 of any 6 following core set measures, with no more than 1 of remaining variables worsening by >30%: • Number of joints with active arthritis • Number of joints with limitation of range of motion • Physician’s Global Assessment of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor) • CHAQ (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability]) • Parent’s Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor) • CRP FAS consisted of all study participants in SS who have no more than one of 6 core components missing at baseline (count of joints with active arthritis, count of joints with limitation of range of motion, Physician’s Global Assessment of Disease Activity score, CHAQ score, Parent’s Global Assessment of Overall Well-Being score and CRP result) for calculating PedACR30/50/70/90.
    End point type
    Secondary
    End point timeframe
    Week 16
    End point values
    Any CZP Dose - Weight group: 10 - < 20 kg Any CZP Dose - Weight group: 20 - <40 kg Any CZP Dose - Weight group: >= 40 kg
    Number of subjects analysed
    18
    63
    112
    Units: percentage of participants
        number (confidence interval 95%)
    22.2 (6.4 to 47.6)
    25.4 (15.3 to 37.9)
    29.5 (21.2 to 38.8)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)
    Adverse event reporting additional description
    TEAEs were defined as AEs starting on or after first administration of CZP and up to 70 days after last dose of study medication. Safety Set (SS) consisted of all study participants in the Enrolled Set (ES) who have received at least 1 dose of study medication.
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    23.1
    Reporting groups
    Reporting group title
    Any CZP Dose - Weight group: 10 - <20 kg
    Reporting group description
    Participants received CZP sc as a fixed dose based on their body weight Q2W or Q4W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.

    Reporting group title
    Any CZP Dose - Weight group: 20 - <40 kg
    Reporting group description
    Participants received CZP sc as a fixed dose based on their body weight Q2W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.

    Reporting group title
    Any CZP Dose - Weight group: >=40 kg
    Reporting group description
    Participants received CZP sc as a fixed dose based on their body weight Q2W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.

    Serious adverse events
    Any CZP Dose - Weight group: 10 - <20 kg Any CZP Dose - Weight group: 20 - <40 kg Any CZP Dose - Weight group: >=40 kg
    Total subjects affected by serious adverse events
         subjects affected / exposed
    5 / 18 (27.78%)
    20 / 63 (31.75%)
    21 / 112 (18.75%)
         number of deaths (all causes)
    0
    0
    3
         number of deaths resulting from adverse events
    0
    0
    3
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Hair follicle tumour benign
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pregnancy, puerperium and perinatal conditions
    Abortion spontaneous
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pregnancy
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pregnancy on contraceptive
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    2 / 112 (1.79%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Pain
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Immune system disorders
    Drug hypersensitivity
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Drug abuse
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Anxiety
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Alcoholism
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Suicidal ideation
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Intentional self-injury
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Investigations
    Transaminases increased
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Jaw fracture
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Forearm fracture
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Lower limb fracture
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Road traffic accident
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    Nervous system disorders
    Idiopathic generalised epilepsy
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    2 / 112 (1.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    Leukocytosis
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Lymphadenopathy
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Ileus
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal motility disorder
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Dysphagia
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Crohn's disease
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Inflammatory bowel disease
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholecystitis
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Nephrolithiasis
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Endocrine disorders
    Adrenal suppression
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Foot deformity
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Juvenile idiopathic arthritis
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Pneumonia
         subjects affected / exposed
    0 / 18 (0.00%)
    5 / 63 (7.94%)
    2 / 112 (1.79%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 5
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Appendicitis
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Disseminated tuberculosis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    Breast abscess
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Appendicitis perforated
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pilonidal cyst
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pharyngitis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Oesophageal candidiasis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pneumonia fungal
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Varicella zoster virus infection
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Varicella
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Tuberculosis liver
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    Tuberculosis
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Serratia bacteraemia
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Septic shock
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    Pyelonephritis acute
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Viral infection
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Any CZP Dose - Weight group: 10 - <20 kg Any CZP Dose - Weight group: 20 - <40 kg Any CZP Dose - Weight group: >=40 kg
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    16 / 18 (88.89%)
    59 / 63 (93.65%)
    98 / 112 (87.50%)
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    3 / 18 (16.67%)
    12 / 63 (19.05%)
    11 / 112 (9.82%)
         occurrences all number
    6
    18
    20
    Cyst
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    2 / 112 (1.79%)
         occurrences all number
    1
    0
    2
    Condition aggravated
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 63 (1.59%)
    2 / 112 (1.79%)
         occurrences all number
    1
    1
    2
    Injection site reaction
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    6 / 112 (5.36%)
         occurrences all number
    0
    2
    9
    Fatigue
         subjects affected / exposed
    0 / 18 (0.00%)
    5 / 63 (7.94%)
    9 / 112 (8.04%)
         occurrences all number
    0
    6
    11
    Injection site pain
         subjects affected / exposed
    2 / 18 (11.11%)
    5 / 63 (7.94%)
    10 / 112 (8.93%)
         occurrences all number
    2
    25
    30
    Drug intolerance
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    2 / 112 (1.79%)
         occurrences all number
    1
    0
    2
    Reproductive system and breast disorders
    Dysmenorrhoea
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 63 (1.59%)
    3 / 112 (2.68%)
         occurrences all number
    1
    3
    6
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    2 / 18 (11.11%)
    10 / 63 (15.87%)
    11 / 112 (9.82%)
         occurrences all number
    2
    16
    21
    Oropharyngeal pain
         subjects affected / exposed
    0 / 18 (0.00%)
    6 / 63 (9.52%)
    15 / 112 (13.39%)
         occurrences all number
    0
    12
    19
    Nasal congestion
         subjects affected / exposed
    2 / 18 (11.11%)
    2 / 63 (3.17%)
    2 / 112 (1.79%)
         occurrences all number
    2
    4
    2
    Epistaxis
         subjects affected / exposed
    0 / 18 (0.00%)
    4 / 63 (6.35%)
    7 / 112 (6.25%)
         occurrences all number
    0
    4
    18
    Rhinorrhoea
         subjects affected / exposed
    1 / 18 (5.56%)
    6 / 63 (9.52%)
    6 / 112 (5.36%)
         occurrences all number
    1
    8
    12
    Psychiatric disorders
    Depression
         subjects affected / exposed
    0 / 18 (0.00%)
    2 / 63 (3.17%)
    8 / 112 (7.14%)
         occurrences all number
    0
    2
    11
    Anxiety
         subjects affected / exposed
    0 / 18 (0.00%)
    2 / 63 (3.17%)
    7 / 112 (6.25%)
         occurrences all number
    0
    2
    7
    Investigations
    Blood creatinine increased
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences all number
    1
    1
    0
    Mycobacterium tuberculosis complex test positive
         subjects affected / exposed
    1 / 18 (5.56%)
    2 / 63 (3.17%)
    1 / 112 (0.89%)
         occurrences all number
    1
    2
    1
    Hepatic enzyme increased
         subjects affected / exposed
    2 / 18 (11.11%)
    1 / 63 (1.59%)
    6 / 112 (5.36%)
         occurrences all number
    2
    1
    7
    C-reactive protein increased
         subjects affected / exposed
    2 / 18 (11.11%)
    1 / 63 (1.59%)
    6 / 112 (5.36%)
         occurrences all number
    2
    2
    6
    Aspartate aminotransferase increased
         subjects affected / exposed
    0 / 18 (0.00%)
    3 / 63 (4.76%)
    6 / 112 (5.36%)
         occurrences all number
    0
    3
    8
    Alanine aminotransferase increased
         subjects affected / exposed
    1 / 18 (5.56%)
    5 / 63 (7.94%)
    9 / 112 (8.04%)
         occurrences all number
    1
    5
    12
    Blood creatine phosphokinase increased
         subjects affected / exposed
    1 / 18 (5.56%)
    5 / 63 (7.94%)
    10 / 112 (8.93%)
         occurrences all number
    1
    8
    12
    Transaminases increased
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences all number
    1
    0
    1
    Blood alkaline phosphatase increased
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    0 / 112 (0.00%)
         occurrences all number
    1
    0
    0
    Injury, poisoning and procedural complications
    Ligament sprain
         subjects affected / exposed
    0 / 18 (0.00%)
    5 / 63 (7.94%)
    9 / 112 (8.04%)
         occurrences all number
    0
    6
    11
    Joint injury
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 63 (1.59%)
    2 / 112 (1.79%)
         occurrences all number
    1
    2
    5
    Radius fracture
         subjects affected / exposed
    2 / 18 (11.11%)
    0 / 63 (0.00%)
    3 / 112 (2.68%)
         occurrences all number
    2
    0
    3
    Contusion
         subjects affected / exposed
    0 / 18 (0.00%)
    3 / 63 (4.76%)
    6 / 112 (5.36%)
         occurrences all number
    0
    4
    7
    Congenital, familial and genetic disorders
    Lichen spinulosus
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    0 / 112 (0.00%)
         occurrences all number
    1
    0
    0
    Nervous system disorders
    Headache
         subjects affected / exposed
    2 / 18 (11.11%)
    7 / 63 (11.11%)
    30 / 112 (26.79%)
         occurrences all number
    2
    16
    56
    Migraine
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 63 (1.59%)
    6 / 112 (5.36%)
         occurrences all number
    0
    1
    9
    Blood and lymphatic system disorders
    Lymphadenopathy
         subjects affected / exposed
    0 / 18 (0.00%)
    5 / 63 (7.94%)
    4 / 112 (3.57%)
         occurrences all number
    0
    6
    4
    Neutropenia
         subjects affected / exposed
    1 / 18 (5.56%)
    4 / 63 (6.35%)
    3 / 112 (2.68%)
         occurrences all number
    2
    5
    7
    Thrombocytopenia
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences all number
    1
    0
    1
    Ear and labyrinth disorders
    Middle ear effusion
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 63 (1.59%)
    1 / 112 (0.89%)
         occurrences all number
    1
    1
    1
    Ear pain
         subjects affected / exposed
    1 / 18 (5.56%)
    3 / 63 (4.76%)
    1 / 112 (0.89%)
         occurrences all number
    1
    5
    1
    Eye disorders
    Conjunctivitis allergic
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 63 (1.59%)
    1 / 112 (0.89%)
         occurrences all number
    1
    1
    2
    Ocular hyperaemia
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    0 / 112 (0.00%)
         occurrences all number
    1
    0
    0
    Hypermetropia
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    0 / 112 (0.00%)
         occurrences all number
    1
    0
    0
    Iritis
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences all number
    2
    0
    2
    Uveitis
         subjects affected / exposed
    1 / 18 (5.56%)
    2 / 63 (3.17%)
    0 / 112 (0.00%)
         occurrences all number
    1
    3
    0
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    1 / 18 (5.56%)
    3 / 63 (4.76%)
    13 / 112 (11.61%)
         occurrences all number
    2
    5
    19
    Diarrhoea
         subjects affected / exposed
    3 / 18 (16.67%)
    5 / 63 (7.94%)
    13 / 112 (11.61%)
         occurrences all number
    4
    5
    14
    Vomiting
         subjects affected / exposed
    3 / 18 (16.67%)
    6 / 63 (9.52%)
    14 / 112 (12.50%)
         occurrences all number
    3
    8
    22
    Abdominal pain
         subjects affected / exposed
    0 / 18 (0.00%)
    8 / 63 (12.70%)
    8 / 112 (7.14%)
         occurrences all number
    0
    9
    12
    Salivary gland mass
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    0 / 112 (0.00%)
         occurrences all number
    1
    0
    0
    Retained deciduous tooth
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    0 / 112 (0.00%)
         occurrences all number
    1
    0
    0
    Dental caries
         subjects affected / exposed
    3 / 18 (16.67%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences all number
    3
    1
    0
    Stomatitis
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 63 (1.59%)
    4 / 112 (3.57%)
         occurrences all number
    1
    2
    4
    Abdominal discomfort
         subjects affected / exposed
    0 / 18 (0.00%)
    4 / 63 (6.35%)
    2 / 112 (1.79%)
         occurrences all number
    0
    4
    2
    Skin and subcutaneous tissue disorders
    Seborrhoeic dermatitis
         subjects affected / exposed
    1 / 18 (5.56%)
    2 / 63 (3.17%)
    1 / 112 (0.89%)
         occurrences all number
    1
    2
    2
    Urticaria
         subjects affected / exposed
    1 / 18 (5.56%)
    4 / 63 (6.35%)
    2 / 112 (1.79%)
         occurrences all number
    1
    7
    2
    Rash
         subjects affected / exposed
    1 / 18 (5.56%)
    7 / 63 (11.11%)
    10 / 112 (8.93%)
         occurrences all number
    1
    7
    13
    Dermatitis atopic
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 63 (1.59%)
    0 / 112 (0.00%)
         occurrences all number
    1
    1
    0
    Musculoskeletal and connective tissue disorders
    Neck pain
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    5 / 112 (4.46%)
         occurrences all number
    1
    0
    5
    Back pain
         subjects affected / exposed
    0 / 18 (0.00%)
    2 / 63 (3.17%)
    6 / 112 (5.36%)
         occurrences all number
    0
    3
    7
    Pain in extremity
         subjects affected / exposed
    0 / 18 (0.00%)
    4 / 63 (6.35%)
    10 / 112 (8.93%)
         occurrences all number
    0
    6
    13
    Arthralgia
         subjects affected / exposed
    2 / 18 (11.11%)
    6 / 63 (9.52%)
    10 / 112 (8.93%)
         occurrences all number
    2
    11
    17
    Juvenile idiopathic arthritis
         subjects affected / exposed
    3 / 18 (16.67%)
    12 / 63 (19.05%)
    20 / 112 (17.86%)
         occurrences all number
    3
    19
    37
    Joint swelling
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    4 / 112 (3.57%)
         occurrences all number
    1
    0
    6
    Tendonitis
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 63 (1.59%)
    2 / 112 (1.79%)
         occurrences all number
    2
    1
    2
    Infections and infestations
    Latent tuberculosis
         subjects affected / exposed
    2 / 18 (11.11%)
    7 / 63 (11.11%)
    2 / 112 (1.79%)
         occurrences all number
    2
    7
    2
    Upper respiratory tract infection
         subjects affected / exposed
    4 / 18 (22.22%)
    16 / 63 (25.40%)
    28 / 112 (25.00%)
         occurrences all number
    11
    41
    62
    Respiratory tract infection
         subjects affected / exposed
    1 / 18 (5.56%)
    12 / 63 (19.05%)
    11 / 112 (9.82%)
         occurrences all number
    6
    22
    15
    Viral infection
         subjects affected / exposed
    2 / 18 (11.11%)
    7 / 63 (11.11%)
    13 / 112 (11.61%)
         occurrences all number
    2
    12
    17
    Pharyngitis streptococcal
         subjects affected / exposed
    0 / 18 (0.00%)
    10 / 63 (15.87%)
    9 / 112 (8.04%)
         occurrences all number
    0
    16
    18
    Pharyngitis
         subjects affected / exposed
    1 / 18 (5.56%)
    9 / 63 (14.29%)
    7 / 112 (6.25%)
         occurrences all number
    1
    11
    9
    Sinusitis
         subjects affected / exposed
    0 / 18 (0.00%)
    5 / 63 (7.94%)
    12 / 112 (10.71%)
         occurrences all number
    0
    6
    20
    Tonsillitis
         subjects affected / exposed
    2 / 18 (11.11%)
    9 / 63 (14.29%)
    6 / 112 (5.36%)
         occurrences all number
    3
    9
    11
    Influenza
         subjects affected / exposed
    1 / 18 (5.56%)
    5 / 63 (7.94%)
    10 / 112 (8.93%)
         occurrences all number
    1
    8
    16
    Conjunctivitis
         subjects affected / exposed
    2 / 18 (11.11%)
    3 / 63 (4.76%)
    7 / 112 (6.25%)
         occurrences all number
    2
    3
    7
    Bronchitis
         subjects affected / exposed
    1 / 18 (5.56%)
    6 / 63 (9.52%)
    6 / 112 (5.36%)
         occurrences all number
    1
    6
    6
    Urinary tract infection
         subjects affected / exposed
    0 / 18 (0.00%)
    4 / 63 (6.35%)
    10 / 112 (8.93%)
         occurrences all number
    0
    4
    23
    Rhinitis
         subjects affected / exposed
    0 / 18 (0.00%)
    8 / 63 (12.70%)
    7 / 112 (6.25%)
         occurrences all number
    0
    12
    9
    Gastroenteritis
         subjects affected / exposed
    0 / 18 (0.00%)
    4 / 63 (6.35%)
    11 / 112 (9.82%)
         occurrences all number
    0
    4
    19
    Nasopharyngitis
         subjects affected / exposed
    4 / 18 (22.22%)
    17 / 63 (26.98%)
    32 / 112 (28.57%)
         occurrences all number
    8
    46
    68
    Ear infection
         subjects affected / exposed
    2 / 18 (11.11%)
    4 / 63 (6.35%)
    4 / 112 (3.57%)
         occurrences all number
    2
    5
    6
    Varicella
         subjects affected / exposed
    4 / 18 (22.22%)
    4 / 63 (6.35%)
    0 / 112 (0.00%)
         occurrences all number
    4
    4
    0
    COVID-19
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    6 / 112 (5.36%)
         occurrences all number
    1
    0
    9
    Tooth infection
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    1 / 112 (0.89%)
         occurrences all number
    2
    0
    1
    Viral rash
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 63 (1.59%)
    1 / 112 (0.89%)
         occurrences all number
    1
    1
    1
    Pneumonia
         subjects affected / exposed
    1 / 18 (5.56%)
    2 / 63 (3.17%)
    0 / 112 (0.00%)
         occurrences all number
    1
    3
    0
    Bacteriuria
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 63 (1.59%)
    1 / 112 (0.89%)
         occurrences all number
    1
    2
    1
    Otitis media acute
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 63 (1.59%)
    2 / 112 (1.79%)
         occurrences all number
    1
    1
    2
    Ascariasis
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 63 (0.00%)
    0 / 112 (0.00%)
         occurrences all number
    1
    0
    0
    Impetigo
         subjects affected / exposed
    1 / 18 (5.56%)
    3 / 63 (4.76%)
    2 / 112 (1.79%)
         occurrences all number
    1
    3
    2
    Gastroenteritis viral
         subjects affected / exposed
    1 / 18 (5.56%)
    3 / 63 (4.76%)
    2 / 112 (1.79%)
         occurrences all number
    1
    3
    2
    Respiratory tract infection viral
         subjects affected / exposed
    2 / 18 (11.11%)
    4 / 63 (6.35%)
    1 / 112 (0.89%)
         occurrences all number
    2
    4
    1
    Viral pharyngitis
         subjects affected / exposed
    1 / 18 (5.56%)
    1 / 63 (1.59%)
    4 / 112 (3.57%)
         occurrences all number
    1
    1
    5

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    26 Aug 2011
    Protocol Amendment 1, dated 26 Aug 2011, was implemented prior to the start of enrollment and submitted to Food and Drug Administration (FDA). The primary purpose of this substantial protocol amendment was to revise the protocol in line with change requests from health authorities following discussions on the CZP pediatric arthritis development program. In addition, a list of anticipated SAEs for CZP in the juvenile idiopathic arthritis (JIA) population was added based on the FDA Final Rule on safety reporting for investigational new drug studies. Further key revisions included updates of eligibility criteria, updates of the protocol to current terminology used in the rheumatology community and to current company standards, and clarification of assessments and concomitant medications.
    06 May 2013
    Protocol Amendment 3 was dated 06 May 2013, and a total of 54 study participants had entered the study at the time of this amendment. The primary purpose of this substantial amendment was to update the exclusion criteria and guidelines related to tuberculosis (TB) detection and monitoring in order to comply with the revised UCB TB Task Force policy applied to all UCB-sponsored studies that include study participants with immunological diseases who are at risk of developing or reactivation of TB infection, which might be associated with the class of tumor necrosis factor inhibitor (TNFi), including the investigational medicinal product (IMP). These instructions are evidence-based and reflect the updated recommendations of various national guidelines (eg, diagnosis of latent TB infection [LTBI] [Centers for Disease Control and Prevention]). This guideline includes the preference of use of tuberculin purified protein derivative skin test (TST) over interferon-gamma release assay (IGRA) in children below the age of 5 years. With the implementation of Protocol Amendment 3, TST was mandatory for study participants from 2 to 4 years of age in this study, unless the study participant had received a Bacille Calmette-Guérin (BCG) vaccination, and IGRA testing was required for study participants from 5 to 17 years of age. An independent Data and Safety Monitoring Board (DSMB) was implemented to conform to the standards for pediatric clinical studies. The DSMB reviewed emerging safety, PK, and efficacy data from the study. Activities were defined in the DSMB charter. Furthermore, this substantial amendment introduced a full interim analysis at Week 24 (Visit 10) involving a complete data analysis for the inclusion in the marketing application for the JIA indication.
    06 May 2013
    Continuation of Protocol Amendment 3: At the same time, the planned analysis at Week 16 (Visit 8) was reduced to an analysis of the American College of Rheumatology Pediatric 30% (PedACR30) response rate required to confirm adequate response of the study population to CZP treatment and to confirm continuation of RA0043. Key revisions also included modifications and clarifications of eligibility criteria related to the diagnosis of JIA, use of disease-modifying antirheumatic drug (DMARDs) and methotrexate (MTX), TB, hepatitis screening panel, Follow-up Period for pregnancy and contraception, and infections. Further revisions were made to clarify study-related procedures (eg, the process of analyzing CZP plasma concentrations in the first cohort of study participants and the completion of parent-reported questionnaires), to clarify the CZP assay methodology, and to correct errors in the previous protocol version (eg, in relation to the core set measures of the American College of Rheumatology Pediatric (PedACR). In addition, the definition of the Physician’s Global Assessment criterion for Clinically Inactive Disease (CID) and clinical remission (CRM) previously defined as "clinical remission on medication") was changed to conform to the most current standard as defined by Wallace et al, 2011.
    01 Aug 2013
    Protocol Amendment 4, dated 01 Aug 2013, was implemented after a total of 78 study participants had entered the study. The primary purpose of this substantial amendment was to implement a change in the dosing algorithm for children and adolescents who were participating currently in RA0043 at the time. Based on the results of the interim population pharmacokinetic (PopPK) analysis conducted in Jun 2013 (report Aug 2013) that included data from 34 pediatric study participants, new enrollment into RA0043 was suspended, effective 17 Jul 2013, and the maintenance dose for study participants already in RA0043 was reduced with Protocol Amendment 4. An overall dose reduction for pediatric study participants of 50% of the dose used in RA0043 at that time was proposed to provide a pragmatic dose that would yield a closer match to the plasma concentration range achieved in adults with the approved dose for RA (CZP 400mg at Weeks 0, 2, and 4 [Visits 2, 4, and 5, respectively] followed by CZP 200mg Q2W thereafter). Additional Unscheduled Visits were implemented, as required, in order to closely monitor the study participants over a period of 12 weeks after the dose change.
    20 Jan 2014
    Protocol Amendment 5, dated 20 Jan 2014, was implemented after a total of 78 study participants had entered the study. The primary purpose of this substantial amendment was to reopen enrollment under the new Reduced CZP Dose, as defined in Protocol Amendment 4 and to update the statistical analyses to account for the changes in the CZP dose. Two CZP dose subgroups were defined as follows: • Original CZP Dose: included all study participants in the Safety Set (SS) who began treatment in accordance with the Original CZP Dose defined for the study (including study participants who underwent a dose reduction under Amendment 4). • Reduced CZP Dose: included all study participants in the SS who began treatment under Protocol Amendment 5 in accordance with the Reduced CZP Dose defined for the study. At the time of Protocol Amendment 4, a total of 78 study participants had entered the study and started treatment on the Original CZP Dose. To allow for a comparison of the group of 78 study participants on the Original CZP Dose with a comparable group of study participants on the revised CZP dose, a further 78 study participants were planned for the Reduced CZP Dose. Thus, the overall number of study participants was increased from 125 to at least 156. Study participants who fulfilled the eligibility criteria but could not enter the study due to the suspended enrollment as of 17 Jul 2013 were allowed to be rescreened. Key changes included the clarification that only study participants who entered the study under Protocol Amendment 5 and began treatment on the Reduced CZP Dose were taken into account for the study stopping rule based on the Week 16 (Visit 8) PedACR30 interim analysis and that a minimum number of 10 study participants in each weight category needed to enter the study for the Reduced CZP Dose.
    20 Jan 2014
    Continuation of Protocol Amendment 5: In addition, the requirement that a study participant’s dosing category may only be changed if the 20 kg and 40 kg weight boundaries are crossed due to weight changes of >2.5 kg and >5 kg, respectively, was removed from the protocol. Applying this requirement at the time of dose reduction would have led to potential underdosing of study participants who just crossed the weight boundary, as they would have had their doses reduced by 50% even though, based on their actual weight, they already fell into the next higher weight category. Furthermore, additional changes were made to the exclusion criteria and guidelines related to TB detection and monitoring to adapt the protocol to the current UCB standard, and descriptions of clinically inactive disease (CID) and clinical remission on medication (CRM) were modified for clarity.
    22 Sep 2016
    Protocol Amendment 7: The primary purpose of this substantial amendment, dated 22 Sep 2016, was to update the protocol in accordance with current UCB TB detection procedures, including the introduction of yearly TB testing and the extension of the prophylactic TB treatment duration from 4 to 8 weeks. Furthermore, it was clarified that long-term efficacy data from study participants who withdrew from the study after Week 56 or initiated any rescue medication use after Week 56 would be analyzed “as observed” and would no longer be imputed as nonresponse or missing. Moreover, a section on “Suspected transmission of an infectious agent via a medicinal product” was added in accordance with current company standards.
    24 Jun 2019
    Protocol Amendment 8: The primary purpose of this substantial amendment, dated 24 Jun 2019, was to reduce the study participants’ burden by limiting the frequency of on-site visits, safety sampling, and efficacy assessments. The frequency of on-site visits was reduced from every 8 weeks to every 16 weeks in this long-term study. At the time of implementing Protocol Amendment 8, all ongoing study participants had at least completed the visit for Week 180. As before, on-site CZP administration between scheduled visits was offered as needed. The frequency of safety sampling (blood sampling and urinalysis) was extended from every 8 weeks to every 16 weeks to reduce the study participants’ burden in line with the updated on-site CZP administration schedule. Safety data collected previously during the study and close evaluation by the DSMB supported the extension of sampling frequency. This longer interval was also implemented for efficacy assessments to further reduce study participants’ burden and was appropriate to describe the long-term efficacy of CZP. UCB also determined there was limited value in collecting ADAb and CZP plasma concentration data after >4 years of CZP exposure. UCB determined that collection of additional samples to determine CZP plasma concentrations and ADAb samples would be of limited utility and an undue burden on the study participants. Discontinuation of blood sample collection for further characterization of CZP PK and immunogenicity was supported by the DSMB as the PK and immunogenicity data available to date were considered sufficient from a safety perspective and for PK characterization.
    27 Apr 2020
    Protocol Amendment 9, dated 27 Apr 2020, was undertaken following an interaction with FDA in Jan 2020 in context of the pJIA Pediatric Research Equity Act (PREA) requirement for CZP. The primary purpose of this substantial amendment was to enroll an additional 30 study participants on the Original CZP Dose in order to adequately assess the exposure levels and clinical experience of CZP in pcJIA at both the Reduced CZP Dose and Original CZP Dose, and also adequately support the safety assessment of the Original CZP Dose. The ECLIA methods, for which selectivity had previously been assessed in the rheumatoid arthritis (RA) matrix, were validated to meet the standards set in the regulatory guidance for analytical procedures and methods validations for drugs and biologics (FDA, Guidance for Industry – Bioanalytical Method Validation, 2018). Sampling for CZP plasma concentration and ADAb was reinitiated for study participants enrolled following Protocol Amendment 9. All study participants enrolled following Protocol Amendment 9 had plasma concentrations of CZP and ADAb analyzed using the ECLIA methods. In addition, PK and ADAb samples (for which sufficient volume and stability data for PK analysis were available) collected in this study prior to Protocol Amendment 9 were reanalyzed with the ECLIA methods. The collective ECLIA-based PK data for this study form the basis of any future CZP modeling and simulation work. In addition, exclusion criteria related to TB, hepatis B, hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) were updated to align with current clinical guidelines in Protocol Amendment 9. After Protocol Amendment 9, study participants on the Reduced CZP Dose were able to switch to the Original CZP Dose at the discretion of the Investigator.

    Interruptions (globally)

    Were there any global interruptions to the trial? Yes
    Date
    Interruption
    Restart date
    16 Jul 2013
    On 16-Jul-2013, the enrollment was temporarily suspended. The decision was not based on safety findings but results from an interim pk-analysis. This analysis had indicated certolizumab pegol plasma levels in the range of those observed in adults with RA but at the upper end of the distribution. As the target was to achieve comparable plasma levels as known from adult patients before, the administered dose was reduced. Protocol Amendment 4 (AMD 4) was created with a 50% reduction of the dose (Reduced Dose, RD). Ongoing patients switched from OD to RD. The first new patient to start on RD was enrolled on 23 April 2014.
    23 Apr 2014

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 17:33:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA